Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
natural missplicing events amplified by an elusive deep intronic mybpc3 variant cause hypertrophic cardiomyopathy
Original title: “Natural Missplicing Events Amplified by an Elusive Deep-Intronic MYBPC3 Variant Cause Hypertrophic Cardiomyopathy.”
left atrium myocardial remodeling and prognostic marker derived from cmr feature tracking in pediatric hypertrophic cardiomyopathy
Original title: “Left Atrium Myocardial Remodeling and Prognostic Marker Derived from CMR Feature Tracking in Pediatric Hypertrophic Cardiomyopathy.”
care pathway for the diagnosis and management of patients with hypertrophic phenotype in the marche region the experience of the marche cardiomyopathies network
Original title: “[Care pathway for the diagnosis and management of patients with hypertrophic phenotype in the Marche Region: the experience of the Marche Cardiomyopathies Network].”
international experience with implantable cardioverter defibrillators for the prevention of sudden death in high risk patients with hypertrophic cardiomyopathy
Original title: “International Experience With Implantable Cardioverter Defibrillators for the Prevention of Sudden Death in High-Risk Patients With Hypertrophic Cardiomyopathy.”
rigosertib reverses hypertrophic cardiomyopathy in noonan syndrome
Original title: “Rigosertib Reverses Hypertrophic Cardiomyopathy in Noonan Syndrome.”
yield of clinical screening in pediatric relatives of hypertrophic cardiomyopathy with negative genetic testing
Original title: “The Yield of Clinical Screening in Pediatric Relatives of Hypertrophic Cardiomyopathy With Negative Genetic Testing.”
pattern of use of conventional medical treatments of heart failure with reduced ejection fraction in end stage hypertrophic cardiomyopathy
Original title: “Pattern of use of conventional medical treatments of heart failure with reduced ejection fraction in end-stage hypertrophic cardiomyopathy.”
midventricular hypertrophic cardiomyopathy with apical aneurysm presenting as persistent st segment elevation mimicking acute myocardial infarction
Original title: “Midventricular Hypertrophic Cardiomyopathy With Apical Aneurysm Presenting as Persistent ST-Segment Elevation Mimicking Acute Myocardial Infarction.”
case report of an s icd recorded asystole due to smart pass deactivation in a patient with non obstructive hypertrophic cardiomyopathy
Original title: “A case report of an S-ICD-recorded asystole due to SMART pass deactivation in a patient with non-obstructive hypertrophic cardiomyopathy.”
phenotypic expansion of gyg1 related disease presenting as hypertrophic cardiomyopathy with brugada phenocopy
Original title: “Phenotypic Expansion of GYG1-Related Disease Presenting as Hypertrophic Cardiomyopathy With Brugada Phenocopy.”
whole exome sequencing identifies rare genetic variants in egyptian patients with hypertrophic cardiomyopathy a pilot study
Original title: “Whole-exome sequencing identifies rare genetic variants in Egyptian patients with hypertrophic cardiomyopathy: a pilot study.”
Braveheart Bio is looking to take on Bristol Myers Squibb in hypertrophic cardiomyopathy, while Attovia Therapeutics wants to challenge Sanofi and Regeneron’s Dupixent. Vogenx, meanwhile, is looking to establish its name in the cardiometabolic space.
Original title: “Braveheart, Attovia, Vogenx keep IPOs ballooning with plans to compete in cardiometabolic, immuno”
exercise training in hypertrophic cardiomyopathy a systematic review meta analysis and meta regression
Original title: “Exercise Training in Hypertrophic Cardiomyopathy: A Systematic Review, Meta-analysis, and Meta-regression.”
genotype predicts heart failure independent of lvef peak vo 2 and nt probnp levels in hypertrophic cardiomyopathy
Original title: “Genotype Predicts Heart Failure Independent of LVEF, Peak VO(2), and NT-proBNP Levels in Hypertrophic Cardiomyopathy.”
Edgewise Therapeutics will now focus on a handful of cardiovascular programs including EDG-7500 for hypertrophic cardiomyopathy thanks to the non-dilutive capital from France’s Servier.
Original title: “Servier frees Edgewise for cardio mission with $2.65B muscular dystrophy deal”
validation of circulating mir 323a 3p and mir 625 3p to classify hypertrophic cardiomyopathy in friedreich s ataxia
Original title: “Validation of circulating miR-323a-3p and miR-625-3p to classify hypertrophic cardiomyopathy in Friedreich's ataxia.”
Myqorzo’s success in “non-obstructive” hypertrophic cardiomyopathy separates it from Bristol Myers Squibb’s rival Camzyos and opens up a multibillion-dollar market opportunity.
Original title: “Cytokinetics heart drug scores in closely watched trial”
unusual hypertrophic cardiomyopathy with severe right ventricular outflow tract obstruction and two septal aneurysms a case report
Original title: “Unusual hypertrophic cardiomyopathy with severe right ventricular outflow tract obstruction and two septal aneurysms: a case report.”
evolution and transformation of hypertrophic cardiomyopathy from a high risk to a treatable low mortality disease with contemporary clinical research strategies
Original title: “Evolution and Transformation of Hypertrophic Cardiomyopathy From a High Risk to a Treatable Low Mortality Disease With Contemporary Clinical Research Strategies.”
odyssey hcm and maple hcm studies the role of cardiac myosin inhibitors in hypertrophic cardiomyopathy obstructive and non obstructive
Original title: “The ODYSSEY-HCM and MAPLE-HCM studies: the role of cardiac myosin inhibitors in hypertrophic cardiomyopathy (obstructive and non-obstructive).”